1-(3,3,5,5-四甲基环己烯-1-基)哌啶 | 127562-51-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-(3,3,5,5-四甲基环己烯-1-基)哌啶
• 英文名称: 3,3,5,5-tetramethyl-1-piperidinocyclohexene
• 英文别名: 1-(3,3,5,5-Tetramethyl-1-cyclohexenyl-1)piperidine；1-(3,3,5,5-Tetramethylcyclohex-1-en-1-yl)piperidine；1-(3,3,5,5-tetramethylcyclohexen-1-yl)piperidine
• CAS: 127562-51-0
• 化学式: C₁₅H₂₇N
• 分子量: 221.386
• InChiKey: DXNNRFNMFQULSO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.87
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-(3,3,5,5-四甲基环己烯-1-基)哌啶 在 甲醇 、 9-borabicyclo[3.3.1]nonane dimer 作用下， 生成 3,3,5,5-Tetramethyl-cyclohexen
  参考文献：
  名称：

  Hydroboration. 86. Convenient conversion of aldehydes and ketones into the corresponding alkenes via hydroboration of their enamines. A remarkably simple synthesis of either (Z)- or (E)-alkenes

  摘要：

  Aldehydes and ketones are converted into the corresponding alkenes via hydroboration of their enamines. Hydroboration of aldehyde enamines by 9-borabicyclo[3.3.1]nonane (9-BBN), followed by methanolysis, affords the corresponding terminal alkenes in 75-90% yields. Unsaturated aldehyde enamines produce the corresponding dienes under these conditions. Enamines derived from substituted cyclic ketones and heterocyclic ketones are readily accommodated in this reaction to afford the corresponding alkenes in very good yields. The synthesis of pure (Z)- or (E)-alkenes is readily achieved from the same acyclic ketone enamine by modification of the hydroboration-elimination procedure: (A) hydroboration by 9-BBN followed by methanolysis or (B) hydroboration by borane methyl sulfide (BMS) followed by methanolysis and hydrogen peroxide oxidation. Mechanistic rationale is provided.

  DOI：

  10.1021/jo00004a038

文献信息

• Unsaturated 1-Amino-alkylcyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
  申请人：——

  公开号：US20030166634A1

  公开（公告）日：2003-09-04

  Unsaturated 1-Amino-alkylcyclohexane compounds which are systemically-active as NMDA, 5HT 3 , and nicotinic receptor antagonists, pharmaceutical compositions comprising the same, method of preparation thereof, and method of treating CNS disorders which involve disturbances of glutamatergic, serotoninergic, and nicotinic transmission, treating immunomodulatory disorders, and antimalaria, antitrypanosomal, anti-Borna virus, anti-HSV and anti-Hepatitis C virus activity.

  不饱和的1-氨基烷基环己烷化合物，作为NMDA、5HT3和尼古丁受体拮抗剂具有系统活性，包括这些化合物的药物组合物，其制备方法，以及治疗涉及谷氨酸能、5-羟色胺能和尼古丁能传导障碍的中枢神经系统疾病，治疗免疫调节性疾病，以及抗疟疾、抗锥虫病、抗博纳病毒、抗HSV和抗丙型肝炎病毒活性的方法。
• Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
  申请人：——

  公开号：US20040087658A1

  公开（公告）日：2004-05-06

  The invention relates to a novel drug combination therapy useful in the treatment of dementia comprising administering an 1-aminocyclohexane derivative such as memantine or neramexane and an acetylcholinesterase inhibitor (AChEI) such as galantamine, tacrine, donepezil, or rivastigmine.

  该发明涉及一种新型药物组合疗法，可用于治疗痴呆，包括给予一种1-氨基环己烷衍生物，如美万特或奈拉美喜，以及一种乙酰胆碱酯酶抑制剂（AChEI），如加兰他明、他克林、多奈哌齐或利伐替明。
• Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase and inhibitors
  申请人：Moebius Hans-Joerg

  公开号：US20090124659A1

  公开（公告）日：2009-05-14

  The invention relates to a novel drug combination therapy useful in the treatment of dementia comprising administering an 1-aminocyclohexane derivative such as memantine or neramexane and an acetylcholinesterase inhibitor (AChEI) such as galantamine, tacrine, donepezil, or rivastigmine.

  本发明涉及一种新型药物组合疗法，用于治疗痴呆症，包括给予1-氨基环己烷衍生物，如美金刚烷或内拉美昔，并且给予乙酰胆碱酯酶抑制剂（AChEI），如加兰他敏、他克林、多奈哌齐或利他林。
• COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS
  申请人：MERZ PHARMA GmbH & CO. KGaA

  公开号：US20140371260A1

  公开（公告）日：2014-12-18

  The invention relates to a novel drug combination therapy useful in the treatment of dementia comprising administering an 1-aminocyclohexane derivative such as memantine or neramexane and an acetylcholinesterase inhibitor (AChEI) such as galantamine, tacrine, donepezil, or rivastigmine.

  本发明涉及一种新型药物组合疗法，用于治疗痴呆症，包括给予1-氨基环己烷衍生物，如美金刚烷或尼拉美昔，以及乙酰胆碱酯酶抑制剂（AChEI），如加兰他敏、他克林、多奈哌齐或利伐他汀。
• SINGARAM, BAKTHAN;RANGAISHENVI, MILIND V.;BROWN, HERBERT C.;GORALSKI, CHR+, J. ORG. CHEM., 56,(1991) N, C. 1543-1549
  作者：SINGARAM, BAKTHAN、RANGAISHENVI, MILIND V.、BROWN, HERBERT C.、GORALSKI, CHR+

  DOI：——

  日期：——